Holen Sie sich die Stockscreener-App
2.24
1.82%
0.04
Handel nachbörslich:
2.24
Schlusskurs vom Vortag:
$2.20
Offen:
$2.16
24-Stunden-Volumen:
7.65M
Relative Volume:
0.70
Marktkapitalisierung:
$2.21B
Einnahmen:
$1.31M
Nettoeinkommen (Verlust:
$-597.65M
KGV:
-2.3093
EPS:
-0.97
Netto-Cashflow:
$-425.62M
1W Leistung:
+13.13%
1M Leistung:
-0.88%
6M Leistung:
-17.34%
1J Leistung:
-12.50%
1-Tages-Spanne:
$2.1401
$2.28
1-Wochen-Bereich:
$1.98
$2.28
52-Wochen-Spanne:
$1.83
$4.27
Immunitybio Inc Stock (IBRX) Company Profile
Firmenname
Immunitybio Inc
Sektor
Branche
Telefon
(844) 696-5235
Adresse
3530 JOHN HOPKINS COURT, SAN DIEGO
Vergleichen Sie IBRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.24 | 2.17B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-20 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | BTIG Research | Buy |
| 2023-05-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Eingeleitet | Jefferies | Buy |
Immunitybio Inc Aktie (IBRX) Neueste Nachrichten
Can ImmunityBio Inc. stock beat market expectations this quarterJuly 2025 Final Week & Stock Market Timing Techniques - ulpravda.ru
Why hedge funds are buying ImmunityBio Inc. stock2025 Investor Takeaways & Free High Accuracy Swing Entry Alerts - ulpravda.ru
ImmunityBio, Inc.'s (NASDAQ:IBRX) Most Bullish Insider, Chief Scientific Officer Patrick Soon-Shiong Must Be Pleased With the Recent 5.1% Gain - 富途牛牛
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
ImmunityBio, Inc. (NASDAQ:IBRX) Short Interest Up 23.1% in December - MarketBeat
ImmunityBio, Inc. (IBRX) Stock Analysis: Exploring a Promising 409.80% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
IMMUNITYBIO INCAMENDS SALE AGREEMENT WITH JEFFERIES LLCSEC FILING - 富途牛牛
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround - Yahoo Finance
ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of “100 Most Influential People in Oncology in 2025” - Business Wire
Immunitybio amends sale agreement with Jefferies LLCSEC filing - marketscreener.com
ImmunityBio Signs Amendment to Open Market Sale Agreement With Jefferies - TradingView — Track All Markets
ImmunityBio Inc Stock Analysis and ForecastShort-Term Trading Alerts & Outstanding Trading Tips - earlytimes.in
ImmunityBio Earnings Notes - Trefis
ImmunityBio, Inc.Common Stock (NQ: IBRX - FinancialContent
ImmunityBio (IBRX) Valuation Check After New ANKTIVA Bladder Cancer Data in The Journal of Urology - Sahm
Latest IBRX Insights: Stock Movement and Corporate Developments - StocksToTrade
ImmunityBio (NASDAQ:IBRX) Shares Down 5.1%Here's What Happened - MarketBeat
3 Growth Companies With Insider Ownership Up To 37% - simplywall.st
ImmunityBio Sees Shift Amid Market Turbulence - timothysykes.com
Analyzing the Surge: ImmunityBio’s Market Impact - StocksToTrade
ImmunityBio (NASDAQ:IBRX) Stock Price Up 8.9%Should You Buy? - MarketBeat
How Investors May Respond To ImmunityBio (IBRX) Bladder Cancer Milestone And EMA Backing For ANKTIVA - Sahm
Can ImmunityBio Inc. stock sustain institutional interestJuly 2025 Snapshot & Fast Moving Trade Plans - ulpravda.ru
Is ImmunityBio Inc. stock vulnerable to regulatory risksQuarterly Profit Review & Free Long-Term Investment Growth Plans - Bölüm Sonu Canavarı
Rate Hike: Can ImmunityBio Inc. (26CA) stock stage a strong rebound this quarterWeekly Profit Analysis & Weekly Consistent Profit Watchlists - moha.gov.vn
Can ImmunityBio Inc. (26CA) stock withstand sector downturnsRate Hike & Weekly Momentum Stock Picks - Улправда
Jefferies lifts ImmunityBio Inc. (IBRX) price target following Anktiva European expansion - MSN
Stop Loss: Why ImmunityBio Inc. stock could benefit from AI revolutionTrade Volume Report & Fast Gain Stock Tips - Улправда
ImmunityBio: Anktiva Revenue Will Ramp, But Competitive Risks Remain - Seeking Alpha
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment - Yahoo Finance
ImmunityBio, Moderna among winners of EU drug recommendations this week - MSN
Is ImmunityBio, Inc. (IBRX) the best NASDAQ stock under $10 to buy? - MSN
Is ImmunityBio, Inc. (IBRX) The Best NASDAQ Stock Under $10 to Buy? - Insider Monkey
Jefferies Lifts ImmunityBio Inc. (IBRX) Price Target Following Anktiva European Expansion - Yahoo Finance
ImmunityBio’s HCW9218 study completion: A potential game-changer for pancreatic cancer treatment - MSN
[Form 4] ImmunityBio, Inc. Insider Trading Activity - Stock Titan
ImmunityBio reports encouraging 3-year bladder cancer treatment data - The Pharma Letter
ImmunityBio (NASDAQ: IBRX) director files insider report with no holdings - Stock Titan
ImmunityBio Reports Strong Long-Term Survival Data For Anktiva In Bladder Cancer Study - Sahm
ImmunityBio Reports 96% Three-Year Bladder Cancer Survival With Anktiva Plus BCG - marketscreener.com
ImmunityBio reports promising 3-year bladder cancer treatment data - Investing.com India
ImmunityBio reports promising 3-year bladder cancer treatment data By Investing.com - Investing.com Nigeria
ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer - Investing News Network
Anktiva® with BCG demonstrates 96% survival from bladder cancer - marketscreener.com
ImmunityBio appoints Bruce Wendel to board - MSN
Assessing ImmunityBio (IBRX) Valuation After EMA Backs Anktiva for BCG‑Unresponsive Bladder Cancer - simplywall.st
ImmunityBio (NASDAQ: IBRX) posts 82% cystectomy avoidance in papillary NMIBC - Stock Titan
ImmunityBio Appoints Bruce Wendel to Board - TipRanks
ImmunityBio, Inc. Appoints Bruce Wendel to the Board, Effective December 12, 2025 - marketscreener.com
[8-K] ImmunityBio, Inc. Reports Material Event | IBRX SEC FilingForm 8-K - Stock Titan
ImmunityBio (NASDAQ:IBRX) Stock Price Down 7.8%Here's Why - MarketBeat
Finanzdaten der Immunitybio Inc-Aktie (IBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
4.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):